Butylparaben

Butylparaben

SCHEMBL6142008

CCCCOC(=O)c1ccc(O)cc1.O=C(O)c1ccc(O)cc1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.87
TSHR P16473 4/20 0.87
LMNA P02545 2/20 0.87
CYP1A2 P05177 2/20 0.87
CYP2C19 P33261 2/20 0.87
CYP2D6 P10635 1/20 0.87
MAPK1 P28482 1/20 0.87
NR1H2 P55055 1/20 0.87
RNASEL Q05823 1/20 0.87
SMN1; SMN2 Q16637 1/20 0.87
ALDH1A1 P00352 2/20 0.70
CHRM1 P11229 1/20 0.70
SLC6A2 P23975 1/20 0.70
KDR P35968 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
PDE4D Q08499 1/20 0.64
ESR2 Q92731 2/20 0.59
CA12 O43570 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butylparaben SCHEMBL23458813 0.95 ESR1 (0.79) ESR1TSHRLMNACYP1A2CYP2C19
Hexyl 4-Hydroxybenzoate SCHEMBL28929472 0.94 TSHR (0.77) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL28872721 0.93 ESR1 (0.93) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL5789201 0.93 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL37477 0.93 TSHR (0.74) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL3647 0.93 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
Terephthalic Acid SCHEMBL21044732 0.93 TSHR (0.74) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL9172319 0.92 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL761983 0.92 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL2325184 0.92 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635589-B Essentially antimicrobial porous matrix composites and methods of making the same 约翰·保罗·威尔逊 2020-07-17 CN disclosed
CN-103415531-B For treating the peptide of skin disorder 器官平衡有限责任公司 2016-10-26 CN disclosed
CN-101309707-A Composition comprising lipoxygenase inhibitor and cyclodextrin BAXTER INT (US) 2008-11-19 CN disclosed
US-20050271692-A1 Topical cosmetic compositions COSMECEUTIC SOLUTIONS PTY. LTD. 2005-12-08 US disclosed
EP-1534214-A1 TOPICAL COSMETIC COMPOSITIONS Cosmeceutic Solutions Pty Ltd (AU) 2005-06-01 EP disclosed
WO-2004000242-A1 TOPICAL COSMETIC COMPOSITIONS COSMECEUTIC SOLUTIONS PTY LTD (AU) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050271692-A1 Topical cosmetic compositions CUTA, MITF, DSG1 ESR1 1257/4885TSHR 2861/4885LMNA 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.